The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 24% over the past year, to $0.8506 per unit.
Market view
disopyramide phosphate · Capsule
5 marketed package NDCs · 2 active manufacturers
Most dispensed: 100 mg · Capsule · #100 capsules/bottle · 150 mg · Capsule · #100 capsules/bottle · 100 mg · Capsule, Gelatin Coated · #100 capsule, gelatin coateds/bottle · 150 mg · Capsule, Gelatin Coated · #100 capsule, gelatin coateds/bottle
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $0.8506 · middle half $0.8506–$1.50 · full range $0.8437–$1.50 · 5 products · 2 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for disopyramide phosphate, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- Norpace CRSep 2, 2026Mfr exitedPfizer Laboratories Div Pfizer Inc · disopyramide phosphate
- Norpace CRSep 2, 2026Mfr exitedPfizer Laboratories Div Pfizer Inc · disopyramide phosphate
- Norpace CRAug 27, 2026New shortageby this manufacturerPfizer Inc.'s Norpace CR (Capsule, Extended Release, 100 mg) is newly in shortage7 companies market norpace cr
- Norpace CRAug 27, 2026New shortageby this manufacturerPfizer Inc.'s Norpace CR (Capsule, Extended Release, 150 mg) is newly in shortage7 companies market norpace cr
- Disopyramide PhosphateAug 19, 2026Price downNADAC $0.85936 → $0.85063 per unit (-1.02%)
- Disopyramide PhosphateAug 19, 2026Price downNADAC $1.53542 → $1.50064 per unit (-2.27%)
- Disopyramide PhosphateAug 19, 2026Price downNADAC $1.53542 → $1.50064 per unit (-2.27%)
- Disopyramide PhosphateAug 19, 2026Price downNADAC $0.85936 → $0.85063 per unit (-1.02%)
- Disopyramide PhosphateAug 19, 2026Price downNADAC $1.53542 → $1.50064 per unit (-2.27%)
- Disopyramide PhosphateAug 19, 2026Price downNADAC $0.85936 → $0.85063 per unit (-1.02%)
Same drug class
Other molecules FDA puts in Antiarrhythmic, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- lidocaine hydrochloride anhydrous and dextrose monohydrate· in shortage
- lidocaine hydrochloride anhydrous· in shortage
- lidocaine hydrochloride,epinephrine bitartrate· in shortage
- lidocaine hydrochloride and epinephrine· in shortage
- lidocaine hydrochloride· in shortage
- lidocaine· in shortage
- 0.5% lidocaine hcl· 1 maker
- 1% lidocaine hci· 1 maker
- 1168 burn spray· 1 maker
- 2.5% lidocaine hcl· 1 maker
- 2677 first aid burn cream· 1 maker
- 4% lidocaine numbing cream· 1 maker
Common questions
- Is Disopyramide phosphate in shortage right now?
- No. FDA does not currently list Disopyramide phosphate in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Disopyramide phosphate?
- 7 companies have marketed Disopyramide phosphate in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Disopyramide phosphate cost?
- The typical pharmacy pays about $0.8506 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.